Evidence map›Paper›PMID 36582237›Full record

ArticleFrontiers in immunology2022

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of

Shang-Hsuan Peng, Bang-Bin Chen, Ting-Chun Kuo, Jen-Chieh Lee, Shih-Hung Yang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shang-Hsuan PengDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Bang-Bin ChenDepartment of Medical Imaging and Radiology, National Taiwan University Hospital, Taipei, Taiwan.
Ting-Chun KuoDepartment of Traumatology, National Taiwan University Hospital, Taipei, Taiwan.
Jen-Chieh LeeDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Shih-Hung YangDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
National Taiwan University Hospital · TWNational Yunlin University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) provide substantial benefits to a small subset of patients with advanced cancer with mismatch repair deficiency (MMRD) or microsatellite instability (MSI), including patients with pancreatic ductal adenocarcinoma (PDAC). However, the long duration of ICI treatment presents a considerable financial burden. We present the case of a 63-year-old woman with metastatic PDAC refractory to conventional chemotherapy. Genetic analyses identified an

Indexed as

AdenocarcinomaPancreatic NeoplasmsDNA-Binding ProteinsFemaleGerm-Line MutationHumansLeucovorinMiddle AgedNivolumabDNA-Binding ProteinsLeucovorinNivolumabcase reportmaintenance therapymismatch repairnivolumabpancreatic ductal adenocarcinoma

Identifiers

PMID36582237
PMCPMC9792834
OpenAlexW4312138127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.